Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

Michael J Seider; Stephanie L Pugh; Corey Langer; Gwen Wyatt; William Demas; Afshin Rashtian; Cathy L Clausen; Jerome David Derdel; Sean F Cleary; Christopher A Peters; Ashok Ramalingam; James E Clarkson; Michael Tomblyn; Rachel A Rabinovitch; Lisa A Kachnic; Lisa A Kachnic; Lawrence B Berk; Nrg Oncology

doi:10.1007/S12149-018-1278-4

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

Michael J Seider
, Stephanie L Pugh
, Corey Langer
, Gwen Wyatt
, William Demas
, Afshin Rashtian
, Cathy L Clausen
, Jerome David Derdel
, Sean F Cleary
, Christopher A Peters
, Ashok Ramalingam
, James E Clarkson
, Michael Tomblyn
, Rachel A Rabinovitch
, Lisa A Kachnic
, Lisa A Kachnic
, Lawrence B Berk
, Nrg Oncology

Yahoo!
NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
University of Pennsylvania
Michigan State University
Salem Regional Medical Center, Salem, OH, USA.
University of Southern California
St. John's University
Penn State Cancer Institute
Memorial Hospital of South Bend
Northeast Radiation Oncology Center, Scranton, PA, USA.
University Hospitals of Cleveland
Singing River Hospital Regional Cancer Center, Pascagoula, MS, USA.
University of South Florida
University of Colorado Denver
Vanderbilt University
Boston Medical Center
Tampa General Hospital

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Nuclear Medicine
Volume	32
Issue number	8
DOIs	https://doi.org/10.1007/S12149-018-1278-4
State	Published - Aug 9 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Survival Analysis
Internal Medicine

Access to Document

10.1007/S12149-018-1278-4License: Unspecified

Cite this

Seider, M. J., Pugh, S. L., Langer, C., Wyatt, G., Demas, W., Rashtian, A., Clausen, C. L., Derdel, J. D., Cleary, S. F., Peters, C. A., Ramalingam, A., Clarkson, J. E., Tomblyn, M., Rabinovitch, R. A., Kachnic, L. A., Kachnic, L. A., Berk, L. B., & Oncology, N. (2018). Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Annals of Nuclear Medicine, 32(8). https://doi.org/10.1007/S12149-018-1278-4

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. / Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al.
In: Annals of Nuclear Medicine, Vol. 32, No. 8, 09.08.2018.

Research output: Contribution to journal › Article › peer-review

Seider, MJ, Pugh, SL, Langer, C, Wyatt, G, Demas, W, Rashtian, A, Clausen, CL, Derdel, JD, Cleary, SF, Peters, CA, Ramalingam, A, Clarkson, JE, Tomblyn, M, Rabinovitch, RA, Kachnic, LA, Kachnic, LA, Berk, LB & Oncology, N 2018, 'Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial', Annals of Nuclear Medicine, vol. 32, no. 8. https://doi.org/10.1007/S12149-018-1278-4

@article{9784b4895e134e72b443f26baae05343,

title = "Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial",

author = "Seider, \{Michael J\} and Pugh, \{Stephanie L\} and Corey Langer and Gwen Wyatt and William Demas and Afshin Rashtian and Clausen, \{Cathy L\} and Derdel, \{Jerome David\} and Cleary, \{Sean F\} and Peters, \{Christopher A\} and Ashok Ramalingam and Clarkson, \{James E\} and Michael Tomblyn and Rabinovitch, \{Rachel A\} and Kachnic, \{Lisa A\} and Kachnic, \{Lisa A\} and Berk, \{Lawrence B\} and Nrg Oncology",

note = "Background Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. Methods NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153).",

year = "2018",

month = aug,

day = "9",

doi = "10.1007/S12149-018-1278-4",

language = "American English",

volume = "32",

journal = "Annals of Nuclear Medicine",

number = "8",

}

TY - JOUR

T1 - Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

AU - Seider, Michael J

AU - Pugh, Stephanie L

AU - Langer, Corey

AU - Wyatt, Gwen

AU - Demas, William

AU - Rashtian, Afshin

AU - Clausen, Cathy L

AU - Derdel, Jerome David

AU - Cleary, Sean F

AU - Peters, Christopher A

AU - Ramalingam, Ashok

AU - Clarkson, James E

AU - Tomblyn, Michael

AU - Rabinovitch, Rachel A

AU - Kachnic, Lisa A

AU - Berk, Lawrence B

AU - Oncology, Nrg

N1 - Background Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. Methods NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153).

PY - 2018/8/9

Y1 - 2018/8/9

UR - https://link.springer.com/article/10.1007/s12149-018-1278-4

U2 - 10.1007/S12149-018-1278-4

DO - 10.1007/S12149-018-1278-4

M3 - Article

VL - 32

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

IS - 8

ER -

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

Disciplines

Access to Document

Other files and links

Cite this